ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Immunosuppression"

  • 2022 American Transplant Congress

    COVID-19 Syndrome After Liver Transplant: Immunosuppression Role and Risk Factors for Mortality

    M. M. Pascale1, F. Frongillo1, G. Bianco1, F. Galiandro2, E. Nure1, S. Agnes1, F. Giovinazzo1

    1General Surgery and Liver Transplant Unit, Fondazione IRCSS - Policlinico "A. Gemelli", Roma, Italy, 2General Surgery Unit, ULSS3 Serenissima, Venezia, Italy

    *Purpose: Data on mortality and immunosuppression role regarding Liver transplant recipients affected by COVID-19 are still under debate. The present study identified risk factors for…
  • 2022 American Transplant Congress

    Disruption of B Cell Population is Associated with Increased Infections in Pediatric Transplant Recipients

    B. Geng, L. Loop, C. Anterasian, D. Mortazavi, J. Kitsen, C. Collins, K. Newton, E. Ingulli

    Pediatrics, UCSD Rady Children's, San Diego, CA

    *Purpose: Solid-organ transplant recipients are placed on long-term immunosuppression, preventing graft rejection but increasing the risk of infection. Pediatric transplant recipients are at increased risk…
  • 2022 American Transplant Congress

    Accepting Rejection in Liver Transplant Recipients Requiring Renal Replacement Therapy: A Practice Paradigm

    S. Farghaly1, T. Sparkes1, B. Masters1, A. Haririan2, N. Jakhete3, R. N. Barth4, D. Maluf5, S. Freedman1

    1Pharmacy, University of Maryland Medical Center, Baltimore, MD, 2Nephrology, University of Maryland Medical Center, Baltimore, MD, 3Hepatology, University of Maryland Medical Center, Baltimore, MD, 4Transplant Surgery, University of Chicago Medical Center, Chicago, IL, 5Transplant Surgery, University of Maryland Medical Center, Baltimore, MD

    *Purpose: The purpose of this study is to evaluate rejection outcomes in those requiring renal replacement therapy (RRT) after liver transplant.*Methods: This was a single…
  • 2022 American Transplant Congress

    The Application of Activated Stem Cells from Human Exfoliated Deciduous Teeth (SHED) in Islet Transplantation for Novel Immunosuppressive Therapy

    K. Ishiyama1, M. Kato2, S. Tsunekawa2, Y. Miwa1, K. Iwasaki1, H. Kamiya2, T. Kobayashi1

    1Division of Kidney Transplantation, Department of Surgery, Aichi Medical University, Nagakute, Japan, 2Division of Diabetes, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan

    *Purpose: While various attempts have been made to improve the efficiency of islet transplantation, we have been working on the analysis of the mechanism of…
  • 2022 American Transplant Congress

    Chimeric Antigen Receptor Regulatory T Cells (CAR-Tregs) Provide Significantly Greater Modulation of Alloimmune Responses Than Alternative Alloantigen-Specific Treg Strategies

    A. S. Kurt1, P. Ruiz1, E. Kodela1, G. Lombardi1, M. Martinez-Llordella2, A. Sanchez-Fueyo1

    1King's College London, London, United Kingdom, 2Quell Therapeutics, London, United Kingdom

    *Purpose: Conferring alloantigen-specificity to ex vivo expanded CD4+CD25+Foxp3+ Tregs increases their capacity to counteract effector alloimmune responses following adoptive transfer into transplant recipients. This has…
  • 2022 American Transplant Congress

    Defining the Longitudinal Dynamics of Immune Cells in Blood in the First Year After Pediatric Liver Transplantation (pLTx)

    E. Chichelnitskiy1, L. Ruhl2, I. Goldschmidt3, A. Karch4, L. Antiga5, D. Debray6, L. Hierro7, D. Kelly8, V. McLin9, E. Nicastro10, J. Pawlowska11, P. Czubkowski11, R. Mikolajczyk12, U. Baumann13, C. Falk14

    1Institute of Transplant Immunology, Hannover Medical School (MHH), Hannover, Germany, 2Institute of Transplant Immunology, MHH, Hannover, Germany, 3Division of Pediatric Gastroenterology and Hepatology, MHH; European Paediatric Liver Transplantation Network, Hannover, Germany, 4Research Group Epidemiological and Statistical Methods, Helmholtz Centre for Infection Research; German Center for Infection Research, TTU-IICH Hannover; Institute for Epidemiology and Social Medicine, University of Münster, Münster, Germany, 5Hannover; Ospedali Riuniti di Bergamo, Bergamo, Italy, 6Hannover; Hôpital Necker-Enfants Malades, Paris, France, 7Hannover; Hospital Infantil Universitario La Paz, Madrid, Spain, 8Birmingham Children's Hospital, Birmingham, United Kingdom, 9Service Spécialités Pédiatriques, Genève, Switzerland, 10Ospedali Riuniti di Bergamo, Bergamo, Italy, 11Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics, The Children’s Memorial Health Institute, Warsaw, Poland, 12German Center for Infection Research, TTU-IICH Hannover; MHH; Institute of Medical Epidemiology, Biostatistics and Medical Informatics, University of Halle, Halle, Germany, 13Birmingham Children’s Hospital, UK; Division of Pediatric Gastroenterology and Hepatology, MHH, Hannover, Germany, 14Institute of Transplant Immunology, MHH; German Center for Infection Research, TTU-IICH, Hannover, Germany

    *Purpose: In the European multicentre “ChilSFree” study we aimed for a deep characterisation of the longitudinal immune dynamics during the first year after pLTx.*Methods: Absolute…
  • 2022 American Transplant Congress

    Ixazomib for Desensitization (IXADES): Results of a Phase II Clinical Trial

    N. Wilson1, S. R. Reese2, L. Ptak3, F. Aziz2, S. Parajuli2, V. Jucaud4, S. Denham4, A. Mishra5, P. Hematti5, A. Djamali2

    1University of Wisconsin, Madison, WI, 2Medicine, University of Wisconsin, Madison, WI, 3Administration, University of Wisconsin, Madison, WI, 4Terasaki Institute, Los Angeles, CA, 5UW Comprehensive Cancer Center, University of Wisconsin, Madison, WI

    *Purpose: Ixazomib is a second-generation oral proteasome inhibitor, FDA approved for the treatment of refractory multiple myeloma. The purpose of the study was (1) to…
  • 2022 American Transplant Congress

    Variable Course of Hepatitis A Virus Infection in Solid Organ Transplant Recipients

    A. Vostal1, J. Husson2, A. Shishido1, N. Jakhete3, E. Moore4, X. Wen5, A. Amoroso2, R. Meier6, E. Wilson2, K. K. Saharia2

    1Div. of Infectious Diseases, Univ. of Maryland Medical Center, Baltimore, MD, 2Div. of Infectious Diseases, Univ. of Maryland School of Medicine and Institute of Human Virology, Baltimore, MD, 3Div. of Hepatology, Univ. of Maryland School of Medicine, Baltimore, MD, 4Dept of Surgery, Brooklyn Hospital Center, Brooklyn, NY, 5Dept. of Surgery, Univ. of Florida, Gainesville, FL, 6Dept. of Surgery, Univ. of Maryland School of Medicine, Baltimore, MD

    *Purpose: Although Hepatitis A virus (HAV) infection is typically a self-limited disease in immunocompetent individuals, the natural history and viral kinetics of HAV in solid…
  • 2022 American Transplant Congress

    Humoral and Cellular Immunity 6 Months After SARS-CoV-2 Infection in Solid-Organ Transplant Recipients

    S. Morris1, S. Courel2, S. Pallikkuth3, S. Pahwa3, A. Fernandez4, S. Anjan1, G. Guerra5, M. Alcaide1, Y. Natori1

    1Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, 2University of Miami Miller School of Medicine, Miami, FL, 3Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, 4Infectious Disease Associates of Tampa Bay, Tampa Bay, FL, 5University of Miami Jackson Memorial Hospital, Miami, FL

    *Purpose: The purpose of this study was to evaluate long term humoral and cellular immunity generated following SARS-CoV-2 infection in solid organ transplant recipients (SOTR).*Methods:…
  • 2022 American Transplant Congress

    Randomized, Phase 4 Study Evaluating the Pharmacokinetics and Tolerability of the New Tacrolimus Tablet Formulation (Tacrobell Tab) in Kidney Transplant Recipients

    A. Han1, E. Cho1, H. Y. Woo1, C. Ara1, H. Lee2, Y. Kim3, Y. Park4, J. Oh4, S. Min1, J. Ha1

    1Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, 2Seoul National University Hospital, Seoul, Korea, Republic of, 3Department of Nephrology, Seoul National University College of Medicine, Seoul, Korea, Republic of, 4Department of Clnical Pharmacology, Seoul National University Hospital, Seoul, Korea, Republic of

    *Purpose: Previous twice-a-day tacrolimus formulations available were capsular and of limited dose formulations (0.5mg, 1mg). Recently a new tablet formulation of tacrolimus with more diverse…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 138
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences